Calu-6Homo sapiens (Human)Cancer cell line

Also known as: CaLu-06, CALU6, Calu6, Calu 6, Calu.6, CALU-6, CaLu-6

🤖 AI SummaryBased on 12 publications

Quick Overview

Calu-6 is a human lung cancer cell line used in cancer research.

Detailed Summary

Calu-6 is a human lung cancer cell line derived from a small cell lung cancer (SCLC) tumor. It is widely used in research to study the molecular mechanisms of cancer, particularly in the context of small cell lung cancer. The cell line has been utilized in studies involving proteomic profiling, genetic mutations, and drug sensitivity. Research on Calu-6 has contributed to understanding the role of specific genes and pathways in cancer progression and therapeutic responses. It is also used to investigate the effects of various treatments and to identify potential targets for cancer therapy.
Generated on 6/15/2025

Basic Information

Database IDCVCL_0236
SpeciesHomo sapiens (Human)
Tissue SourcePleural effusion[UBERON:UBERON_0000175]

Donor Information

Age61
Age CategoryAdult
SexFemale
Racecaucasian

Disease Information

DiseaseLung adenocarcinoma
LineageLung
SubtypeLung Adenocarcinoma
OncoTree CodeLUAD

DepMap Information

Source TypeATCC
Source IDACH-000264_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Arg196Ter (c.586C>T)Unspecified-PubMed=25275298
MutationSimpleKRASp.Gln61Lys (c.180_181TC>CA) (c.180_181delinsCA)Heterozygous-Unknown, Unknown, Unknown, PubMed=12794755, PubMed=12068308, PubMed=1855224

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
12
D13S317
11
D16S539
13
D18S51
12,16
D19S433
13
D21S11
31
D2S1338
17,26
D3S1358
16
D5S818
11
D7S820
10
D8S1179
10,14
FGA
22
Penta D
13
Penta E
5,14
TH01
9
TPOX
8
vWA
17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Lung cancer cell lines as tools for biomedical discovery and research.

Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.

J. Natl. Cancer Inst. 102:1310-1321(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication.

Mitsudomi T.

Int. J. Cancer 106:45-51(2003).

Mutations of the BRAF gene in human cancer.";

Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Nature 417:949-954(2002).

Alterations of integrin expression in human lung cancer.";

Takahashi T., Ueda R.

Jpn. J. Cancer Res. 84:168-174(1993).

Mutations and altered expression of p16INK4 in human cancer.";

Harris C.C.

Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994).

In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers.

Takahashi T., Takahashi T.

Cancer Res. 55:514-517(1995).

Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.

Rousset M., Zweibaum A., Fogh J.

Cancer Res. 41:1165-1170(1981).

Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.

Wright W.C., Daniels W.P., Fogh J.

J. Natl. Cancer Inst. 66:239-247(1981).

Heterogeneity in the radiation survival curves and biochemical properties of human lung cancer cell lines.

Mitchell J.B.

J. Natl. Cancer Inst. 73:801-807(1984).

Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium.

Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D.

Cancer Res. 46:798-806(1986).

Human tumor lines for cancer research.";

Fogh J.

Cancer Invest. 4:157-184(1986).

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Cancer Res. 48:589-601(1988).

Evidence for thromboxane biosynthesis in established cell lines derived from human lung adenocarcinomas.

Hubbard W.C., Alley M.C., McLemore T.L., Boyd M.R.

Cancer Res. 48:2674-2677(1988).

Metabolic activation of 4-ipomeanol in human lung, primary pulmonary carcinomas, and established human pulmonary carcinoma cell lines.

Adelberg S., Czerwinski M.J., McMahon N.A., Eggleston J.C., Boyd M.R.

J. Natl. Cancer Inst. 82:1420-1426(1990).

p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines.

Gerwin B.I., Harris C.C.

Cancer Res. 51:4090-4096(1991).